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Abstract:  
Background: Lymphangioleiomyomatosis (LAM) is a rare disease of women. Decline in lung 
function is variable making appropriate targeting of therapy difficult. We used unbiased 
serum proteomics to identify markers associated with outcome in LAM.   
Methods: 101 women with LAM and 22 healthy controls were recruited from the National 
Centre for LAM (Nottingham, UK). 152 DNA and serum samples with linked lung function 
and outcome data were obtained from patients in the NHLBI LAM Registry (USA). Proteomic 
analysis was performed on a discovery cohort of 50 LAM and 20 control sera using a SCIEX 
SWATH mass spectrometric workflow. Protein levels were quantitated by ELISA and SNPs in 
GC encoding Vitamin D Binding Protein (VTDB) genotyped.  
Results: Proteomic analysis showed VTDB was 2.6 fold lower in LAM than controls. Serum 
VTDB was lower in progressive compared with stable LAM (p=0.001) and correlated with 
diffusing capacity (p=0.01). Median time to death or lung transplant was reduced by 46 
months in those with CC genotypes at rs4588 and 38 months in those with non-A containing 
haplotypes at rs7041/4588 (p=0.014 and 0.008 respectively). 
Conclusions: The VTDB axis is associated with disease severity and outcome, and GC 
genotype could help predict transplant free survival in LAM. 
Abstract word count: 200  
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Introduction:  
Lymphangioleiomyomatosis (LAM) is a rare multi-system disease characterised by lung cysts 
and lymphatic abnormalities. The disease is almost exclusively restricted to women, of 
whom it affects around 9 per million and can occur both sporadically and in those with 
tuberous sclerosis complex (TSC)[1, 2]. In LAM, cysts progressively replace the lung 
parenchyma leading to recurrent pneumothorax and often respiratory failure over a 
variable period of years[3]. Lymphatic obstruction leads to chyloptysis, chylous effusions 
and ascites. Around half of patients with sporadic LAM and most with TSC-LAM also have 
angiomyolipomas, a benign tumour, generally occurring in the kidneys[2]. The lungs and 
lymphatics of patients are infiltrated by LAM cells: a clonal, metastatic cell with a combined 
smooth muscle and melanocyte phenotype characteristic of perivascular epithelioid cell 
neoplasms[4]. LAM cells have bi-allelic TSC mutations[5] which lead to hyper-activation of 
the mechanistic target of rapamycin (mTOR), a component of two multi-protein complexes, 
controlling proliferation, migration, autophagy and metabolism[6].  
Most women with LAM lose lung function at an accelerated rate with FEV1 declining by 70-
140ml per year[7, 8] however, some progress rapidly whilst others can remain stable for 
many years[3, 9]. Treatment with mTOR inhibitors prevents loss of lung function in most 
with progressive disease[8-10]. Recognising progressive disease in individuals with mild lung 
function impairment is important, although generally requires multiple measurements over 
a prolonged period[7]. Markers of disease activity are therefore required to predict those at 
risk of loss of lung function to allow treatment before this occurs. Further, stratification of 
patients with active disease could reduce the size, duration, cost and feasibility of phase II 
studies of new therapies. 
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A number of clinical and serum prognostic factors have been identified. Elevated serum 
Vascular Endothelial Growth Factor-D (VEGF-D) is associated with both the presence of 
LAM[11] and more rapid loss of lung function.  Presentation with dyspnoea rather than 
pneumothorax and a response to bronchodilators have been associated with worse 
outcomes[12-14] whereas post-menopausal status is associated with slower lung function 
loss[7, 15]. Despite this, it is not possible to accurately predict prognosis within individuals.  
Here we have used serum proteomics to identify proteins associated with the presence and 
severity of LAM and identified that changes in Vitamin D Binding Protein (VTDB) and it gene, 
Group-Specific Component (GC), are associated with disease severity and survival in LAM. 
 
Materials and Methods: 
Patients and sample collection 
101 women with LAM and 22 healthy control women were recruited between 2011 and 
2016 from the National Centre for LAM, Nottingham, UK, (Figure 1). Ethical approval was 
obtained from the East Midlands Research Ethics Committee (13/EM/0264). All subjects 
provided written informed consent. A second cohort of 152 women with LAM recruited 
between 1998 and 2001 in the National Heart Lung and Blood Institute (NHLBI) LAM 
Registry was used for replication and to study long term survival[16] (Figure 1). Baseline 
chest and abdominal CT, serial lung function serum and DNA at recruitment was obtained 
for all subjects. Clinical assessment, lung function and sample analysis for both cohorts are 
described in the online supplement. Due to duration of follow-up, all-cause mortality or the 
need for lung transplant, was only available for NHLBI Registry cohort and was obtained by 
querying the United States National Death Index and the United Network for Organ Sharing 
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databases. As data on the use of rapamycin was not available for this cohort, outcome data 
were censored at 2010 before rapamycin was widely used for the treatment of LAM in the 
USA. 
 
Proteomics 
70 serum samples (50 LAM and 20 controls) were analysed on a SCIEX TripleTOF 6600 mass 
spectrometer hyphenated to an Eksigent nanoLC 425 system using the SCIEX SWATH mass 
spectrometric workflow[17]. Tandem mass spectrometry (MS/MS) spectra were searched 
using ProteinPilot 5.0 (SCIEX) with the Swissprot human database (Jan 2015) at 1 % false 
discovery rate with an identification focus on biological modifications. SWATH data were 
aligned to library files in PeakView (SCIEX), uploaded and processed using the SCIEX 
OneOmics platform[18]. Full details are given in the online supplement. 
 
Serum protein quantification 
Serum VTDB, Alpha-1 acid glycoprotein 1 (A1AG1) and VEGF-D were determined in the UK 
cohort using Quantikine ELISA kits DVDBP0, DAGP00 and DVED00 respectively (R & D 
Systems, UK). VTDB in the NHLBI Registry was measured using Quantikine ELISA kit 
DVDBP0B (R & D Systems, UK).  
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Genotyping 
DNA was extracted from whole blood using the Wizard Genomic DNA Purification Kit 
(Promega, UK). As GC genotype varies across populations, genetic analysis was confined to 
those of European ancestry. 65 UK LAM samples and 168,141 unrelated control women of 
European ancestry from the UK Biobank were genotyped using the Affymetrix Axiom UK 
Biobank array. Ancestry was determined from k-means clustering of the first two principal 
components from the genome-wide SNP data[19]. The NHLBI LAM registry cohort were 
genotyped using KASP PCR genotyping (LGC Genomics service. Herts, UK) with ancestry 
obtained by questionnaire.  
 
Statistical analysis 
Proteins identified by proteomics were considered differentially expressed if they were ≤ -2 
or ≥ 2 Log2 fold different between groups with a confidence ≥ 0.7 as described[18]. Welch’s 
t-test or Mann-Whitney U tests were used for categorical data, linear regression and 
Spearman’s correlation for continuous data. GC allele frequencies for women with LAM and 
UK Biobank controls were compared using Chi-squared tests[20]. Survival analyses were 
performed using Kaplan-Meier plots with differences analysed by Mantel-Cox log rank test. 
Analyses were performed using GraphPad Prism v7 and SPSS v24 (IBM). 
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Results: 
 
Discovery cohort and serum proteomics 
The first 50 UK women with LAM enrolled who were not treated with an mTOR inhibitor and 
20 healthy control women formed the discovery cohort. The cohort was divided into more 
progressive and stable disease based upon a retrospective loss of FEV1 of more than 50ml/yr 
over a mean period of observation of 11 (± 4) years. Those with progressive disease had 
lower FEV1, DLCO and higher serum VEGF-D values but were of similar age and disease 
duration as those with stable disease (Table 1).  
Mass spectrometry of the 70 serum samples identified 126 proteins including the serum 
proteins albumin, haemopexin, acid glycoprotein, immunoglobulins, complement 
components, clotting factors, proteases and protease inhibitors (Table E1). VTDB levels were 
2.6-fold lower (confidence 0.65) in LAM than healthy control women (Table E2). To identify 
markers of severity we compared the proteomic profiles of those with stable and 
progressive disease. A1AG1 levels were 3.6-fold higher (confidence 0.70) in those with 
progressive compared with stable disease. Comparison of pre- and post-menopausal 
women with LAM did not identify differentially expressed proteins at the pre-specified 
confidence level. 
 
Serum protein quantification  
Mass spectrometry findings were validated using ELISAs for VTDB and A1AG1. Consistent 
with the proteomic findings, serum VTDB was lower in 50 women with LAM in the UK 
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discovery cohort and 27 women with LAM in the UK replication cohort than in controls 
(p=0.007 and p=0.002, respectively). For the 77 women in the UK discovery (50) and 
replication cohorts (27) combined, VTDB was 273 ± 96 µg/ml in LAM and 347 ± 92 µg/ml in 
control women (p=0.002, Figure 2a).  When assessed by ELISA, A1AG1 was higher in women 
with LAM in the discovery and replication cohorts than control women (p=0.04 and 
p=0.0001, respectively). For all women with LAM, A1AG1 was 910 ± 478 µg/ml and 619 ± 
270 µg/ml in control women (p=0.004, Figure 2b).  
 
VTDB is associated with disease severity 
VTDB was significantly lower in those with more progressive, compared with more stable 
lung disease at recruitment (progressive 221 ± 89 µg/ml, stable 299 ± 90 µg/ml, p=0.001, 
Figure 3a). VTDB level was positively associated with percent predicted DLCO (p=0.01) but 
not forced vital capacity (p=0.09) or FEV1 (p=0.23, Figure 3b-d). A1AG1 was higher in those 
with stable, compared with progressive disease (stable 1004 ± 525 µg/ml, progressive 753 ± 
341 µg/ml, p=0.01, Figure E1) but was not related to lung function. Levels of VTDB were not 
associated with age, age at diagnosis, menopausal status, nature of presenting symptom, 
the presence of tuberous sclerosis, angiomyolipomas, lymphatic disease or serum VEGF-D 
level (data not shown). The distribution of VTDB was similar in the 77 untreated and 24 
women receiving treatment with rapamycin for LAM, whereas A1AG1 was higher in the 
rapamycin treated group (rapamycin treated 1132 ± 474 µg/ml, untreated 910 ± 478 µg/ml 
(p=0.031, Figure E2). 
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Association of GC genotypes with LAM and serum VTDB 
As GC genotype varies according to ancestry, genetic analyses were restricted to the 65 
individuals in the UK and 145 individuals in the NHLBI LAM cohorts of European origin. Two 
SNPs within GC at rs7041 and rs4588 define the major GC haplotypes (i) GC2 where rs7041 
(G) and rs4588 (C), (ii) GC1F where rs7041(G) and rs4588 (A) and (iii) GC1S where rs7041 (T) 
and rs4588 (A). The allele frequencies at these SNPs in the UK and NHLBI LAM cohorts did 
not differ from control women in the UK Biobank or each other (Table E3). In both LAM 
cohorts, as in the general population, serum VTDB was dependent on GC genotype[21] 
(Figure E3).  
 
Association of VTDB protein and genotype with outcome 
From the UK cohort, 91 women with LAM had lung function measured over greater than 
one year after enrolment (64 untreated and 27 receiving rapamycin for LAM). The mean 
period of observation was 19 months, corresponding to 144 patient years of observation. 
Within the NHLBI LAM cohort, 136 women with untreated LAM had lung function measured 
over greater than one year after enrolment with a mean period of observation of 40 
months, corresponding to 500 patient years of observation. Serum VTDB was not associated 
with prospective change in lung function in either cohort (Table 2).  
Within the NHLBI LAM Registry cohort, those with low serum VTDB, the AA genotype at 
rs4588 and TT at rs7041 had the highest rates of loss of FEV1 and DLCO, although not 
significantly so (Table 3). We then examined the relationship of the VTDB axis with time to 
death or lung transplant in the NHLBI LAM Registry cohort. Although time to death or 
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transplant was not associated with serum VTDB level (p=0.76, Figure 4a) or rs7041 
genotype, there was an association with rs4588 genotype. Median time to death or 
transplant for the AA or AC genotype at rs4588 was 150 months compared with 104 months 
for CC (p=0.014, Figure 4b). Median time to death or transplant for all haplotypes with an A 
allele at rs4588 (including GC1F and GC1S haplotypes) was 150 months compared with 112 
months for haplotypes with no A allele present (including GC2, p=0.008, Figure 4c).  
 
Discussion 
We have shown for the first time the VTDB axis is associated with both severity and 
outcome in women with LAM. VTDB levels were associated with DLCO and disease activity at 
assessment. Those with progressive disease, defined by a loss of FEV1 of more than 50 
ml/yr, tended to have lower levels of VTDB than those with more stable disease with a loss 
of FEV1 of less than 50 ml/yr, despite being matched for age and other clinical 
manifestations. Haplotypes of GC were associated with the time to death or lung transplant. 
As such, GC genotype is the first genetic host factor found to influence transplant free 
survival in LAM. 
VTDB is a glycosylated alpha-globulin produced by the liver, kidneys, adipose tissue and 
neutrophils. Coded for by the GC gene on chromosome 4q, two SNPs in exon 11; rs7041 
(Glu416Asp) and rs4588 (Thr420Lys) define the three major haplotypes of VTDB: GC1F: 
416Asp/420Thr, GC1S: 416Glu/420Lys and GC2: 416Asp/420Lys with serum VTDB level 
related to these SNPs[21]. VTDB binds 25(OH)-vitamin D and 1,25(OH)2-vitamin D, although 
vitamin D levels are far exceeded by the transport capacity of VTDB. Serum levels of VTDB 
and vitamin D are unrelated in many diseases studied including Chronic Obstructive 
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Pulmonary Disease (COPD)[22]. The GC variants have differing affinities for vitamin D: the 
complexities of the VTDB isoforms, vitamin D and their impact on lung disease are not yet 
clear[23].  
The mechanism relating GC genotype and serum VTDB is also unknown: rs7041 and rs4588 
are intronic SNPs and neither are in linkage disequilibrium with known promotor or 
enhancer SNPs, nor are they known to affect protein stability. Factors other than GC 
genotype, including epigenetics, may also influence serum VTDB levels, as although serum 
VTDB is lower in women with LAM than controls, GC genotype in our study was not 
different. 
Our findings reflect the complexity of both the VTDB axis and LAM. We observed that lower 
serum VTDB was associated with lower lung function and more active lung disease at 
presentation. As VTDB is not associated with other aspects of the LAM phenotype including 
the presence of angiomyolipoma or lymphatic disease it is likely that VTDB axis is not related 
to LAM per se, but as in other lung diseases may alter the tissue response to disease. 
Importantly, GC genotype was associated with time to death or lung transplantation. The 
strongest effect being for the GC1F and GC1S haplotypes, which were associated with an 
increase in median survival of over three years. Interestingly, this and other GC variants 
associated with improved survival were not those associated with the lowest serum VTDB 
levels. VTDB is a multifunctional protein which may impact upon the response to lung 
damage in a number of ways. GC1F and GC1S are associated with increased macrophage 
activation over GC2[22] and increased macrophage activation may be protective in LAM, 
either by enhancing protective neutrophil responses or enhancing the chemotactic effect of 
complement-derived C5a[24][25]. VTDB also acts as an actin scavenging protein and 
therefore has the potential to influence disease by different mechanisms including altered 
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innate immunity and tissue repair. Different GC haplotypes are already associated with 
susceptibility to lung disease: GC1F being associated with an enhanced risk of COPD over 
GC1S and GC2[26].  
These observations underscore the multiple potential functions of VTDB, how these 
functions may be related to genotype and the complex relationship with lung disease. The 
complexity of LAM, a multisystem disease, is also likely to be important. For example, VTDB 
protein is associated with DLCO but not FEV1, FVC or event-free survival. Whilst FEV1 is 
generally used to study the natural history of LAM, DLCO is usually impaired before FEV1 and 
may better reflect early parenchymal damage in LAM with loss of FEV1 occurring later due to 
loss of elastic recoil and premature airway closure brought about by parenchymal damage. 
Pulmonary vascular disease, host defence, peripheral muscle function and other processes 
potentially affected by VTDB function may also contribute to survival.  
One of the strengths of our study was the use of an unbiased proteomic method that 
identified VTDB as a protein of interest in LAM. The involvement of the vitamin D axis in 
other diseases associated with tissue remodelling make our findings biologically 
plausible[27]. Our study also has limitations however, including the low number of control 
samples, technical limitations and those inherent in studying rare diseases. Firstly, VTDB was 
one of only two proteins differentially expressed in the serum of women with LAM and the 
proteomic methodology used did not identify other LAM markers such as VEGF-D. VEGF-D is 
expressed at picomolar levels[28], whereas VTDB is present a micromolar levels suggesting 
that only relatively abundant serum proteins with robust differences between women with 
LAM and healthy controls could be detected using this proteomic strategy. It is therefore 
likely that other potentially useful biomarkers remain undiscovered. Consistent with this, 
A1AG1, also known as orosomucoid, the other protein linked to the presence of LAM in our 
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proteomic screen, is another relatively abundant plasma alpha globulin, comprising 1-3% of 
plasma proteins. As A1AG1 is an acute phase protein, already recognised as a biomarker of 
overall survival in many populations we did not study it further[29]. As LAM is very rare, 
studying the disease relies upon cohorts accumulated over longer periods of time. Although 
both cohorts studied used protocol driven assessments to capture key data including lung 
function, there are some differences in the data available for these groups. Although the 
two cohorts used were similar in terms of age and lung function, prospective change in lung 
function differed, probably due to the use of rapamycin in the UK cohort resulting in 
reduced loss of FEV1. Conversely, due to time of recruitment, long term survival prior to 
Rapamycin use can now only be studied in the NHLBI registry cohort. Current individuals 
with progressive disease, including those in the UK cohort studied here, tend to be treated 
with rapamycin[30] and longer periods of observation are needed to study the effect of the 
VTDB protein or genotype on survival in women with LAM treated with rapamycin. 
In conclusion, low levels of VTDB are associated with poor lung function in LAM and GC 
genotypes are associated with long-term outcome. Our findings suggest that the VTDB axis 
is a host factor that may protect against lung damage in LAM and could be of prognostic 
significance. Further studies are required to validate our findings and understand how the 
VTDB isoforms modulate lung damage in LAM and other diseases. 
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Table 1. Clinical data for cohorts studied. 
 
 
 
*: mean ± standard deviation at recruitment. †: present at any time in disease course (%). 
N/A: not applicable. N/T: not available for testing. Disease duration in the UK LAM cohort 
was first symptom to enrolment whilst in the NHLBI cohort disease duration was from 
diagnosis to enrolment. In the NHLBI cohort, menopause was assumed if ≥ 50 years of age. 
  
  
  
UK Discovery cohort UK 
Replication 
cohort 
UK 
Rapamycin 
treated 
USA 
NHLBI 
cohort 
Healthy 
controls All Stable Progressive 
n 50 26 24 27 24 152 22 
Age (years)* 50.6 ± 10.9 50.9 ± 11.8 50.3 ± 10.0 49.4 ± 13.9 46.4 ± 9.7 45.4 ± 9.0 35.0 ± 11.7 
Disease duration 
(years)* 
13.9 ± 11.1 14.2 ± 11.4 13.5 ± 11.1 9.1 ± 9.5 13.1 ± 9.5 4.6 ± 4.3 N/A 
Angiomyolipoma† 72 77 67 55 54 N/T N/A 
Lymphatic disease† 16 15 17 23 25 N/T N/A 
TSC† 14 19 8 15 21 N/T N/A 
Pneumothorax† 48 50 46 40 46 N/T N/A 
Post-menopause† 34 42 25 30 25 48 N/A 
FEV1 (% predicted)* 68.9 ± 20.6 76.4 ± 18.9 60.8 ± 19.5 77.4 ± 23.4 46.7 ± 14.8 74.1 ± 27.5 N/A 
DLCO (% predicted)* 59.8 ± 15.8 68.9 ±   12.7 50.0 ± 12.9 62.9 ± 17.1 43.3 ± 12.3 55.7 ± 25.6 N/A 
VEGF-D (pg/ml)* 1327 ± 1187 985 ± 833 1698 ± 1405 1275 ± 1527 1082 ± 1257 N/T 397 ± 125 
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Table 2. Prospective change in FEV1 and DLCO and relationship to VTDB 
 UK NHLBI 
 untreated p rapamycin p untreated p 
n 64  27  136  
ΔFEV1 (ml/yr)* -32.6 ± 111.2 n/s 24.3 ± 141.4 n/s -94.7 ± 96.2 n/s 
ΔDLCO (mmol/min/kPa/yr)* -0.2 ± 0.40 n/s -0.17 ± 0.23 n/s -0.23 ± 0.31 n/s 
VTDB (µg/ml)* 273 ± 96 - 281 ± 105 - 255 ± 53.4 - 
 
* mean (standard deviation). p value for Spearman’s correlation with serum VTDB. 
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Table 3. Relationship of VTDB genotype with clinical features, serum VTDB and change in 
lung function in the NHLBI LAM Registry cohort 
SNP rs4588 rs7041 
Genotype AA CA CC p TT GT GG p 
n 11 46 74  25 57 48  
Age at diagnosis 37.4 (6.7) 42.1 (9.9) 40.6 (9.2) n/s 39.9 (7.6) 41.8 (9.7) 40.5 (9.6) n/s 
Age at recruitment 40.9 (6.4) 47.2 (9.4) 45.3 (8.9) - 43.8 (7.5) 46.4 (9.4) 45.4 (9.3) - 
FEV1 (% predicted) 88.0 (21.0) 78.8 (25.2) 72.9 (29.4) n/s 79.9 (26.8) 79.0 (30.2) 72.0 (24.0) n/s 
DLCO (% predicted) 58.3 (17.5) 59.5 (22.5) 57.0 (29.3) n/s 56.3 (18.2) 58.1 (30.8) 58.9 (23.2) n/s 
VTDB (µg/ml) 220 (36) 245 (57) 266 (52) 0.022 233 (43) 250 (57) 270 (53) 0.026 
ΔFEV1 (ml/yr) -125 (142) -78 (81) -99 (97) n/s -135 (126) -80 (84) -94 (94) n/s 
ΔDLCO 
(mmol/min/kPa/yr) 
-0.35 (0.23) -0.21 (0.36) -0.22 (0.3) n/s -0.26 (0.27) -0.20 (0.35) -0.26 (0.27) n/s 
 
Mean (and standard deviation) are shown for women with LAM of European ancestry. Data 
for percent predicted FEV1, DLCO, VTDB and age at recruitment were all at entry to the study. 
ΔFEV1 and ΔDLCO are prospective changes from recruitment. Linear regression was used to 
model the relationship between genotype, clinical factors and VTDB.  
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Figure legends: 
 
Figure 1. Enrolment and samples tested. Recruitment and access to samples and lung 
function data in the UK and NHLBI LAM cohorts. The UK discovery cohort consisted of 50 
serum samples from individuals with LAM, the UK replication cohort comprised 27 LAM 
serum samples and the USA NHLBI LAM cohort 152. PFT: pulmonary function test. 
 
Figure 2. Serum VTDB and A1AG1 in LAM and healthy controls. (a) Women with LAM had 
lower levels of serum Vitamin D Binding Protein (VTDB) compared with healthy control 
women (p=0.002). (b) Women with LAM had higher levels of serum Alpha-1-Acid 
Glycoprotein (A1AG1) compared with healthy control women (p=0.004). 
 
Figure 3. VTDB is associated with disease severity. (a) Lower levels of serum VTDB were 
associated with progressive, compared with stable LAM (p=0.001). (b) VTDB level is 
positively correlated with percent predicted DLCO (p=0.01). (c) VTDB was not associated with 
percent predicted FVC (p=0.09) or (d) percent predicted FEV1 (p=0.23).  
 
Figure 4. Survival analysis for VTDB level and GC genotype in the NHLBI LAM Registry 
cohort. (a) Overall time to death or transplant did not differ with serum VTDB level (low 
(147 - 221 µg/ml), medium (222 - 275 µg/ml) and high (276 - 413 µg/ml. (p=0.76). (b) 
Individuals with the AA or AC genotype at rs4588 had greater time to death or transplant 
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than those with the genotype CC (p=0.014). (c) Haplotypes with an A allele at rs4588 (GC1F 
and GC1S) were associated with longer time to death or transplant (p=0.008). 
 
Figures: 
Figure 1. 
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Figure 2. 
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Figure 4. 
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Supplementary Methods 
 
Patients and sample collection 
101 women with LAM and 22 healthy control women were recruited between 2011 and 2016 
from the National Centre for LAM, Nottingham, UK, hence-forth termed the UK cohort. Ethical 
approval was obtained from the East Midlands Research Ethics Committee (13/EM/0264). For 
healthy controls, age and ethnicity were recorded. All subjects provided written informed 
consent. Clinical history, presence of TSC, angiomyolipoma, lymphatic disease, menopausal 
status and drug treatment were recorded. Lymphatic disease was defined as the presence of 
chylous collections in the chest or abdomen, lymphangioleiomyomas or lymphadenopathy 
due to LAM visible on CT scanning of the chest abdomen and pelvis. Disease duration was 
calculated as the time from first symptom attributable to LAM as previously described7. Blood 
samples were taken at enrolment and processed within one hour of phlebotomy. Whole 
blood collected in serum separator tubes were allowed to clot for 1 hour at room temperature 
and separated by centrifugation at 1000 g for 10 minutes. Blood and serum samples were 
stored at -80 °C until analysis.  
A second cohort of 243 subjects recruited between 1998 and 2001 in the National Heart Lung 
and Blood Institute (NHLBI) LAM Registry to study the natural history of LAM was used as a 
replication cohort and to study long term survival. This cohort has been described in detail 
previously18. Serum and DNA samples at enrolment, available from 152 of these 243 subjects, 
along with clinical and prospective lung function data were obtained from the National 
Disease Research Interchange who now curate the resource. Outcome data, either all-cause 
mortality or the need for lung transplant in the period following baseline assessment, were 
obtained by querying the United States National Death Index and the United Network for 
Organ Sharing databases. As data on the use of rapamycin was not available for this cohort, 
outcome data were censored at 2010 before rapamycin was widely used for the treatment of 
LAM in the USA. Suitable samples for serum protein measurement, genotyping or lung 
function over greater than one year’s duration was not available in all subjects (Figure 1). The 
numbers included in individual analyses are stated in the results. 
Lung function was measured at either Nottingham University Hospitals NHS Trust or the 
referring centre in the USA according to ERS/ATS standards. Prospective change in lung 
function was calculated as the difference between FEV1 and DLCO measured at recruitment 
and last follow up visit expressed in ml/year for FEV1 (ΔFEV1) and as ml/min/kPa/yr for DLCO 
(ΔDLCO). To reduce variation in measurement of disease progression, only values spanning 
one year or longer were used for this analysis7. Classification into stable or progressive disease 
at presentation was performed by calculating retrospective loss of FEV1 until the time of 
enrolment between the first recorded FEV1 value and the FEV1 at study enrolment divided by 
the time interval and expressed in ml/year. Those with a retrospective ΔFEV1 of less than -50 
ml/yr were arbitrarily classified as more stable and greater than -50 ml/yr as more 
progressive. 
Fifty women with LAM from the UK cohort who had not been treated with rapamycin formed 
the initial proteomic discovery population. A further 27 untreated patients from the UK were 
used as a replication cohort and 24 who were receiving rapamycin for treatment of LAM at 
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recruitment were also studied (Table 1). The discovery cohort was subdivided into those with 
stable and more progressive disease based upon retrospective loss of lung function.  
 
 
Proteomics 
Serum was diluted and filtered at 2 µm to remove any particulates to a final 1 in 45 dilution 
in 100 mM Triethylammonium bicarbonate buffer. An alkylation and reduction step adding 
2µL 0.5 mM Dithiothreitol (DTT) with 45 min shaking at 56 ᵒC followed by 7.15 µL of 140 mM 
Iodoacetamide and 30 min incubation in darkness at room temperature. The reaction was 
then quenched using 1.95 µL of 0.5 mM DTT. Samples were digested with 1.95 µL of 1 µg/µL 
trypsin (T656720UG, Sigma, UK) over 17 hrs at 37°C while shaking/agitating after which 
samples were lyophilised in a speed vac and re-suspended at decreasing concentrations of 
acetonitrile (ACN) to a final mixture of 40 µL and 5% ACN 0.1% formic acid (FA). After high 
speed centrifugation, supernatants were transferred to appropriate tubes for mass 
spectrometric analysis. The Biognosis HRM retention time standard was added for 
downstream alignment. Samples were analysed on a SCIEX TripleTOF 6600 mass 
spectrometer hyphenated to an Eksigent nanoLC 425 system operating in micro flow (5 
µL/min). The SCIEX SWATH mass spectrometric workflow17 was utilised for relative protein 
quantitation, wherein data acquired from a quantitative data independent (DIA) SWATH, are 
assembled against libraries of protein identified using a data dependent acquisition. 
Chromatographic separation for protein identification (Information Dependent 
Acquisition/IDA) was over an 87 min gradient, 4 µL direct injection on a YMC 25 cm x 0.3mm 
Triart-C18 column (12nm, 3µm particle size) with a gradient of 3 % mobile phase B (2% 
acetonitrile, 5% DMSO in 0.1% FA) to 30 % over 38 min; to 40% B at 73 min, 80 % B at 75 min, 
held for 3 min then returned to 3 % over 1 min. Chromatographic separation for SWATH runs 
was conducted as above but on a 57 min gradient of 3 % mobile phase B (2% ACN, 5% DMSO 
in 0.1% FA)  to 30 % over 38 min; to 40 % B at 43 min, 80 % B at 45 min held for 3 min then 
returned to 3 % over 1 min. The mass spectrometer set up and method settings consisted of 
a Duospray™ source (SCIEX) with a 50 µm electrode at +5500V (gas settings GS1 15; GS2 0; 
CUR 25; TEMP 0). IDA was carried out using parameters of Top 30 (TOFMS 250 ms 
accumulation time, production 60 ms, total cycle time 2.1 s); charge state 2 - 4 above a 
threshold of 200 cps; dynamic exclusion for 10 seconds using rolling collision energy 
(optimised for m/z of target ion). SWATH methods consisted of 100 variable windows 
optimised for serum and cell lysate proteins. MS/MS spectra were searched using ProteinPilot 
5.0 (SCIEX) with the Swissprot human database (Jan 2015) at 1 % false discovery rate with an 
identification focus on biological modifications. SWATH data were aligned to the library files 
in PeakView (SCIEX) and uploaded to the SCIEX OneOmics platform for processing, 
compilation, assembly and annotation of SWATH data. 
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Supplementary results 
 
Supplementary table E1. Serum proteins identified by proteomic screen in LAM and 
control serum. 
 
Protein Name UniProt ID Full name 
A1AG1 P02763 Alpha-1-acid glycoprotein 1 
A1AT P01009 Alpha-1-antitrypsin 
A1BG P04217 Alpha-1B-glycoprotein 
A2GL P02750 Leucine-rich alpha-2-glycoprotein 
A2MG P01023 Alpha-2-macroglobulin 
ACTG P63261 Actin, cytoplasmic 2 
AFAM P43652 Afamin 
ALBU P02768 Serum albumin 
AMBP P02760 Protein AMBP 
ANGT P01019 Angiotensinogen 
ANT3 P01008 Antithrombin-III 
APOA P08519 Apolipoprotein(a) 
APOA1 P02647 Apolipoprotein A-I 
APOA2 P02652 Apolipoprotein A-II 
APOA4 P06727 Apolipoprotein A-IV 
APOB P04114 Apolipoprotein B-100 
APOC2 P02655 Apolipoprotein C-II 
APOC3 P02656 Apolipoprotein C-III 
APOD P05090 Apolipoprotein D 
APOE P02649 Apolipoprotein E 
APOF Q13790 Apolipoprotein F 
APOH P02749 Beta-2-glycoprotein 1 
APOL1 O14791 Apolipoprotein L1 
APOM O95445 Apolipoprotein M 
C1QC P02747 Complement C1q subcomponent subunit C 
C1R P00736 Complement C1r subcomponent 
C1S P09871 Complement C1s subcomponent 
C4BPA P04003 C4b-binding protein alpha chain 
CAMP P49913 Cathelicidin antimicrobial peptide 
CBPN P15169 Carboxypeptidase N catalytic chain 
CD44 P16070 CD44 antigen 
CD5L O43866 CD5 antigen-like 
CERU P00450 Ceruloplasmin 
CFAB P00751 Complement factor B 
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CFAH P08603 Complement factor H 
CFAI P05156 Complement factor I 
CLUS P10909 Clusterin 
CO2 P06681 Complement C2 
CO3 P01024 Complement C3 
CO4B P0C0L5 Complement C4-B 
CO5 P01031 Complement C5 
CO6 P13671 Complement component C6 
CO8A P07357 Complement component C8 alpha chain 
CO8G P07360 Complement component C8 gamma chain 
CO9 P02748 Complement component C9 
CXCL7 P02775 Platelet basic protein 
FA12 P00748 Coagulation factor XII 
FBLN1 P23142 Fibulin-1 
FCG3A P08637 Low affinity immunoglobulin gamma Fc region receptor III-A 
FCN2 Q15485 Ficolin-2 
FETUA P02765 Alpha-2-HS-glycoprotein 
FHR3 Q02985 Complement factor H-related protein 3 
FHR5 Q9BXR6 Complement factor H-related protein 5 
FIBA P02671 Fibrinogen alpha chain 
FINC P02751 Fibronectin 
FOXN3 O00409 Forkhead box protein N3 
GELS P06396 Gelsolin 
H2AX P16104 Histone H2AX 
HBA P69905 Hemoglobin subunit alpha 
HBB P68871 Hemoglobin subunit beta 
HDAC1 Q13547 Histone deacetylase 1 
HEMO P02790 Hemopexin 
HMMR O75330 Hyaluronan mediated motility receptor 
HPT P00738 Haptoglobin 
HPTR P00739 Haptoglobin-related protein 
HRG P04196 Histidine-rich glycoprotein 
HS12B Q96MM6 Heat shock 70 kDa protein 12B 
HS90B P08238 Heat shock protein HSP 90-beta 
HV101 P01742 Immunoglobulin heavy variable 1-69 
HV304 P01765 Immunoglobulin heavy variable 3-23 
HV305 P01766 Immunoglobulin heavy variable 3-13 
HV306 P01767 Immunoglobulin heavy variable 3-53 
HV311 P01772 Immunoglobulin heavy variable 3-33 
IBP3 P17936 Insulin-like growth factor-binding protein 3 
IC1 P05155 Plasma protease C1 inhibitor 
IGHA1 P01876 Ig alpha-1 chain C region 
IGHA2 P01877 Ig alpha-2 chain C region 
IGHD P01880 Ig delta chain C region 
IGHG1 P01857 Ig gamma-1 chain C region 
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IGHG2 P01859 Ig gamma-2 chain C region 
IGHG3 P01860 Ig gamma-3 chain C region 
IGHM P01871 Ig mu chain C region 
IGJ P01591 Immunoglobulin J chain 
IGKC P01834 Ig kappa chain C region 
IGLL5 B9A064 Immunoglobulin lambda-like polypeptide 5 
ITIH1 P19827 Inter-alpha-trypsin inhibitor heavy chain H1 
ITIH2 P19823 Inter-alpha-trypsin inhibitor heavy chain H2 
ITIH4 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 
K1024 Q9UPX6 UPF0258 protein KIAA1024 
K1C19 P08727 Keratin, type I cytoskeletal 19 
KANK3 Q6NY19 KN motif and ankyrin repeat domain-containing protein 3 
KCNC4 Q03721 Potassium voltage-gated channel subfamily C member 4 
KI67 P46013 Proliferation marker protein Ki-67 
KIFC2 Q96AC6 Kinesin-like protein KIFC2 
KLKB1 P03952 Plasma kallikrein 
KNG1 P01042 Kininogen-1 
KV102 P01594 Immunoglobulin kappa variable 1-33 
KV106 P01598 Immunoglobulin kappa variable 1-5 
KV305 P01623 Immunoglobulin kappa variable 3-20 
KV308 P04207 Immunoglobulin kappa variable 3-15 
KV309 P04433 Immunoglobulin kappa variable 3-11 
KV404 P06314 Immunoglobulin kappa variable 4-1 
LAC2 P0CG05 Ig lambda-2 chain C regions 
LG3BP Q08380 Galectin-3-binding protein 
LIPB2 Q8ND30 Liprin-beta-2 
LV106 P04208 Immunoglobulin lambda variable 1-47 
LV302 P80748 Immunoglobulin lambda variable 3-21 
LV403 P01717 Immunoglobulin lambda variable 3-25 
PEDF P36955 Pigment epithelium-derived factor 
PGRP2 Q96PD5 N-acetylmuramoyl-L-alanine amidase 
PK3CG P48736 
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma 
isoform 
PLF4 P02776 Platelet factor 4 
PLMN P00747 Plasminogen 
PON1 P27169 Serum paraoxonase/arylesterase 1 
PROP P27918 Properdin 
PROS P07225 Vitamin K-dependent protein S 
RET4 P02753 Retinol-binding protein 4 
SAA4 P35542 Serum amyloid A-4 protein 
SHBG P04278 Sex hormone-binding globulin 
SHC1 P29353 SHC-transforming protein 1 
THRB P00734 Prothrombin 
TRFE P02787 Serotransferrin 
TRPV2 Q9Y5S1 Transient receptor potential cation channel subfamily V member 2 
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TSP1 P07996 Thrombospondin-1 
VTDB P02774 Vitamin D-binding protein 
VTNC P04004 Vitronectin 
 
Supplementary table E2. Comparison of protein expression between women with LAM 
and control women.  
 
  LAM vs control 
Protein 
 
UniProt ID 
 
Fold change 
(Log2) 
Confidence 
 
VTDB P02774 -2.6 0.65 
ITIH4 Q14624 -0.5 0.34 
HMMR O75330 0.5 0.31 
FETUA P02765 -2.8 0.30 
AMBP P02760 -0.5 0.28 
TRFE P02787 -2.0 0.22 
ALBU P02768 0.5 0.21 
FIBA P02671 -0.4 0.17 
ITIH2 P19823 0.5 0.16 
IGHG3 P01860 3.1 0.16 
SAA4 P35542 0.7 0.15 
KI67 P46013 -1.3 0.15 
HEMO P02790 0.5 0.13 
APOL1 O14791 -0.5 0.13 
VTNC P04004 -0.5 0.12 
APOA1 P02647 0.8 0.12 
CERU P00450 -0.5 0.12 
CXCL7 P02775 -0.5 0.12 
GELS P06396 2.1 0.12 
LV106 P04208 -1.0 0.11 
CFAB P00751 -0.5 0.11 
KIFC2 Q96AC6 1.7 0.10 
A1AT P01009 -0.6 0.09 
CO2 P06681 -0.5 0.09 
CFAH P08603 -0.3 0.09 
APOH P02749 2.8 0.09 
THRB P00734 -0.3 0.08 
CO3 P01024 -0.3 0.08 
IGHM P01871 0.6 0.08 
CBPN P15169 -0.4 0.08 
IGHA1 P01876 -0.7 0.07 
CLUS P10909 0.3 0.07 
C4BPA P04003 0.5 0.07 
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KNG1 P01042 0.3 0.07 
TRPV2 Q9Y5S1 -1.0 0.06 
PK3CG P48736 -1.2 0.06 
CD5L O43866 2.4 0.05 
KV106 P01598 -1.4 0.05 
IGJ P01591 -0.5 0.05 
APOA2 P02652 0.3 0.05 
A2MG P01023 4.0 0.05 
HRG P04196 0.4 0.05 
AFAM P43652 0.4 0.05 
LAC2 P0CG05 -3.0 0.05 
APOA4 P06727 0.4 0.05 
LV302 P80748 0.5 0.05 
A2GL P02750 0.8 0.05 
CO4B P0C0L5 2.3 0.05 
APOA P08519 -1.1 0.05 
APOD P05090 -0.4 0.05 
HBA P69905 0.9 0.05 
PLMN P00747 -0.3 0.04 
HV101 P01742 -2.0 0.04 
KV309 P04433 0.5 0.04 
KV102 P01594 0.4 0.04 
IC1 P05155 0.5 0.04 
CO8A P07357 -0.3 0.04 
PROS P07225 0.4 0.04 
IGKC P01834 0.5 0.04 
PON1 P27169 0.9 0.04 
SHC1 P29353 0.3 0.04 
HPT P00738 1.1 0.04 
IBP3 P17936 -0.5 0.04 
RET4 P02753 -0.7 0.03 
HDAC1 Q13547 -0.4 0.03 
C1S P09871 0.2 0.03 
C1QC P02747 0.4 0.03 
KCNC4 Q03721 -0.9 0.03 
CAMP P49913 -0.5 0.03 
LG3BP Q08380 -0.7 0.03 
ANT3 P01008 -0.3 0.03 
A1AG1 P02763 0.8 0.03 
H2AX P16104 -1.2 0.03 
FA12 P00748 -0.6 0.03 
PROP P27918 -0.5 0.03 
CFAI P05156 -0.3 0.03 
A1BG P04217 0.3 0.03 
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IGLL5 B9A064 0.5 0.03 
IGHG1 P01857 -0.7 0.02 
CO9 P02748 -0.3 0.02 
ACTG P63261 -0.8 0.02 
HBB P68871 0.9 0.02 
APOB P04114 -0.5 0.02 
APOC3 P02656 -0.4 0.02 
FINC P02751 -0.3 0.02 
IGHD P01880 -1.0 0.02 
FBLN1 P23142 -0.5 0.02 
APOC2 P02655 0.5 0.02 
PGRP2 Q96PD5 -0.4 0.02 
APOF Q13790 -0.7 0.02 
ITIH1 P19827 0.5 0.02 
FCN2 Q15485 0.5 0.02 
FHR3 Q02985 0.6 0.01 
KANK3 Q6NY19 -0.9 0.01 
FCG3A P08637 -0.5 0.01 
ANGT P01019 -0.4 0.01 
HV311 P01772 -0.6 0.01 
C1R P00736 -0.7 0.01 
APOE P02649 0.4 0.01 
CO6 P13671 -0.7 0.01 
HS12B Q96MM6 -0.3 0.01 
APOM O95445 0.2 0.01 
IGHA2 P01877 0.3 0.01 
TSP1 P07996 0.5 0.01 
IGHG2 P01859 0.9 0.01 
SHBG P04278 -0.8 0.01 
K1024 Q9UPX6 -0.4 0.01 
LV403 P01717 -0.2 0.01 
HPTR P00739 -0.6 0.01 
FOXN3 O00409 0.7 0.01 
KLKB1 P03952 -0.9 0.01 
CO5 P01031 -0.6 0.01 
HS90B P08238 -0.6 0.01 
HV304 P01765 -0.6 0.01 
HV305 P01766 0.6 0.01 
PLF4 P02776 -0.2 0.00 
KV305 P01623 0.7 0.00 
PEDF P36955 0.6 0.00 
 
Protein differences are expressed as fold change ranked by significance. 
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Supplementary table E3. GC allele frequencies in control women, UK and NHLBI LAM 
cohorts 
 
Genotype Cohort p value 
Controls UK LAM NHLBI LAM 
control vs. 
UK LAM 
control vs. 
NHLBI LAM 
UK LAM vs. 
NHLBI LAM n 168141 65 
rs7041 rs4588 
145 146 
rs7041 
GG 31 22 37 
 -  0.076 0.29 0.075 GT 50 49 43 
TT 19 29 20 
rs4588 
AA 8 14 
 -  
8 
0.20 0.17 0.43 AC 42 34 34 
CC 50 52 58 
 
Percentage allele frequencies are shown for women of European ancestry in the three 
cohorts. Allele frequencies were compared using the Chi-squared test. 
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Supplementary figure E2. Serum Vitamin D Binding Protein (VTDB) levels in patients with LAM 
untreated or treated with rapamycin.  Serum A1AG1 levels in rapamycin treated LAM compared with 
untreated LAM, (*p=0.031). 
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Supplementary figure E1. Relationship between serum Alpha1-acid glycoprotein (A1AG1) and 
disease activity. Serum A1AG1 of women with stable LAM is significantly higher than those with 
progressive disease (p=0.01). 
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Supplementary figure E3. Relationship between GC genotype and serum VTDB. In the UK LAM 
cohort, the presence of the T allele at rs7041 was dose dependently associated with lower serum 
VTDB levels (n=63, p<0.0001, panel a) although rs4588 was not associated with serum VTDB level 
(p=0.57, panel b). In the NHLBI Registry cohort, the T allele at rs7041 and the A allele at rs4588 were 
dose dependently associated with lower serum VTDB levels (n=139, p=0.010 and n=140, p=0.035 
respectively, panels c and d). Haplotype analysis combining the allelic information at both SNPs 
showed the presence of the minor alleles at either rs7041 or rs4588 (T and A respectively) were 
associated with lower serum VTDB levels in both the UK and NHLBI cohorts, p<0.0001 and p=0.0018, 
respectively, panels e and f).  
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